Valuation: EyePoint, Inc.

Market Cap 543M 466M 435M 399M 751M 51.91B 763M 5.13B 2.01B 26.04B 2.04B 1.99B 86.09B P/E 2026 *
-1.71x
P/E 2027 * -2.36x
Enterprise Value 220M 189M 176M 162M 305M 21.06B 310M 2.08B 815M 10.56B 827M 809M 34.92B EV / Sales 2026 *
128x
EV / Sales 2027 * 12.8x
Free-Float
96.41%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: EyePoint, Inc.

1 day-11.83%
1 week-57.60%
Current month-53.35%
1 month-54.86%
3 months-54.28%
6 months-62.72%
Current year-68.72%
1 week 3.95
Extreme 3.95
14.76
1 month 3.95
Extreme 3.95
14.76
Current year 3.95
Extreme 3.95
18.87
1 year 3.95
Extreme 3.95
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
40.3
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap.
18/8/26 Buy

Director

10,600 0.0126%
10/7/26 Fiscal year

Chief Executive Officer

41,393 0.0494%
30/6/26 Fiscal year

Chief Technology Officer

14,625 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-11.67%-57.60%-50.35%-62.79% 543M
-0.87%+4.55%+79.17%+129.79% 1,141B
-0.42%+3.77%+52.06%+62.50% 659B
-0.36%+5.46%+26.47%+76.15% 470B
+0.80%+2.13%+41.01%+45.50% 366B
-0.20%+2.54%+23.95%+40.98% 302B
-0.45%+2.44%+0.15%+12.37% 254B
-1.15%+4.45%+47.21%+67.40% 239B
-0.30%+0.22%-13.51%-52.60% 207B
-1.16%+5.62%+22.89%+92.14% 183B
Average -1.59%-1.65%+22.91%+41.14% 382.15B
Weighted average by Cap. -0.50%+4.30%+45.02%+73.10%

Financials

2026 *2027 *
Net sales 1.72M 1.48M 1.38M 1.26M 2.38M 164M 2.42M 16.26M 6.37M 82.47M 6.46M 6.32M 273M 17.92M 15.37M 14.36M 13.17M 24.77M 1.71B 25.17M 169M 66.33M 859M 67.29M 65.83M 2.84B
Net income -345M -296M -276M -253M -476M -32.94B -484M -3.26B -1.28B -16.52B -1.29B -1.27B -54.62B -292M -251M -234M -215M -404M -27.91B -410M -2.76B -1.08B -14B -1.1B -1.07B -46.29B
Net Debt -323M -277M -259M -237M -446M -30.85B -453M -3.05B -1.19B -15.47B -1.21B -1.19B -51.16B -314M -270M -252M -231M -435M -30.06B -442M -2.97B -1.16B -15.07B -1.18B -1.16B -49.84B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
20/08/26 USD 5.590 -11.27% 1,561,005
19/08/26 USD 6.300 +15.17% 8,792,924
18/08/26 USD 5.470 +12.32% 16,238,028
17/08/26 USD 4.870 -66.98% 52,268,276
14/08/26 USD 14.75 +9.42% 2,511,098
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
6.300USD
Average target price
27.36USD
Spread / Average Target
+334.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock